 |
 |
FROM: Haaretz (Israel) July 6, 2004 Teva gets `approvable' letter for Parkinson's drug By Eli Daniel Teva announced yesterday that it has received an approvable letter from the U.S. Food and Drug Administration for once-daily Agilect, or rasagiline mesylate, as a treatment for Parkinson's disease. An "approvable" letter brings Teva a step closer to obtaining U.S. permission to market the drug. The letter relates to rasagiline as an initial monotherapy (taken alone) in early Parkinson's patients and as adjunct therapy in moderate-to-advanced stages of the disease. "We are very pleased to receive this approvable letter, which is a major regulatory milestone in the approval process of Agilect," said Israel Makov, president and CEO of Teva. Rasagiline acts by blocking the breakdown of dopamine, a substance made by brain cells, which is essential to movement. http://www.haaretz.com/hasen/spages/447726.html ------------------------------------------------------------------------- ------- ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn